CD4 and hepatocellular carcinoma: Peripheral blood tests of HCC patients after RFA suggest that RFA may activate myeloid DCs by upregulating the levels of proinflammatory cytokines, including tumor necrosis factor (TNF)‐α and IL‐1b, thereby activating CD4+ T cells.206